Navigation Links
GlaxoSmithKline Accelerates Review of Exelixis' XL880
Date:8/23/2007

XL880 has attractive pharmaceutical properties, with high solubility and oral bioavailability. In preclinical studies, XL880 inhibited its targets with nanomolar potency, and retained potent activity against mutationally activated forms of MET found in hereditary papillary renal cell carcinomas. The compound also demonstrated dose-dependent tumor growth inhibition in models of breast cancer, colorectal cancer, non-small cell lung cancer, and glioblastoma, and has been shown to cause substantial tumor regression in all models tested. Significantly, a single dose of XL880 completely inhibited tumor growth for 21 days in a glioblastoma model.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase 2 and Phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential efficacy of XL880 and the timing of the submission of XL880 to GSK. Words such as "expects," "will," "expedite," "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and u
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)
2. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
3. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
4. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
5. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
6. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
7. Medicures MEND-CABG Trial Results Published in Peer Reviewed Journal
8. Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
9. Salix Pharmaceuticals Previews Digestive Disease Week 2007
10. Reatas Synthetic Triterpenoids Profiled in Nature Reviews Cancer
11. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Originally discovered by Welfide (Mitsubishi ... Industries, Ltd) as an inflammatory drug, pranoprofen was ... Co., Ltd under the trade name of pranopulin ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Tobramycin ... Tobramycin is a traditional antibiotic whose eye drop and ... treatment of potential infection or inflammation caused by eye ... are able to produce tobramycin, among which ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by AstraZeneca plc, ... an important drug for the treatment of schizophrenia. ... quetiapine was listed in the Catalogue of Drugs ...
Breaking Medicine Technology:Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2
... Genomics announced today that,the company entered into a ... (JHU) to commercialize products that identify,patients at risk ... a suite of,issued and pending JHU patents covering ... (IGF2). Orion,s simple blood-based risk,assessment test is being ...
... , - Data Published in the British ... Negative Impact on Overall Survival or Tumour,Progression, ... controlled,studies in 2,301 cancer patients shows that treating ... on survival, tumour,progression or deaths caused by blood ...
Cached Medicine Technology:Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University 2New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients 2
(Date:8/30/2015)... Fl (PRWEB) , ... August 30, 2015 , ... ... Executive Vice President Jeff Fernandez will lead the expansion of global cosmeceutical and ... and skin care experience having spent the last 25 years working in operations, ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President ... the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has served ... college expand its reach and impact through innovative technologies and strategies. , “I am ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, ... Applied Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and ... and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... extend and improve the lives of patients, according to a newly published report. ... to read the full article. , The authors of the new paper ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 , ... ... unofficial end of summer (which astronomically, officially ends on September 22nd this year). For ... summer-induced cyber security hangovers linger on which could prove far more costly than a ...
Breaking Medicine News(10 mins):Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... of North Carolina at Chapel Hill School of Medicine ... large clinical study to evaluate the role played by ... study, which was part of the Johnston County Osteoarthritis ... who inherited a specific pattern of genetic variations in ...
... sunless tanning products, and an intervention promoting these products ... and sunburns among adult women, according to two reports ... , one of the JAMA/Archives journals. Ultraviolet radiation ... category and is the most common avoidable cause of ...
... to any length to try to become part of a ... eating something dicey, or doing illicit drugs, according to a ... "Social exclusion prompts people to use money and ... Mead (Tilburg University), Roy F. Baumeister (Florida State University), Tyler ...
... By Kathleen Doheny HealthDay Reporter , ... studies may help breast cancer patients and their ... after mastectomy. One study finds that about ... having had a mastectomy with immediate reconstruction develop ...
... HealthDay Reporter , MONDAY, Sept. 20 (HealthDay News) -- ... of hearings Monday on whether to recommend approval of ... the advisers recommend approval, it would mark the first ... America,s dinner plates and restaurant menus. Currently, genetically modified ...
... College of Law at Arizona State University has been ... Law Network, which launches today to provide legal and ... challenges such as food safety, health reform and emergency ... Program (PHLPP) received a $1.325 million grant from the ...
Cached Medicine News:Health News:UNC researchers identify genetic patterns that may predict osteoarthritis 2Health News:UNC researchers identify genetic patterns that may predict osteoarthritis 3Health News:Use of sunless tanning products common in teens, may encourage sun safety in women 2Health News:Use of sunless tanning products common in teens, may encourage sun safety in women 3Health News:Money, drugs and chicken feet? What consumers will do for social acceptance 2Health News:Breast Reconstruction After Mastectomy: Now or Later? 2Health News:Breast Reconstruction After Mastectomy: Now or Later? 3Health News:FDA Advisers Weigh Approval of Genetically Modified Salmon 2Health News:FDA Advisers Weigh Approval of Genetically Modified Salmon 3Health News:11-state regional Public Health Law Network office to be established at ASU College of Law 2Health News:11-state regional Public Health Law Network office to be established at ASU College of Law 3
This handy reference contains all of the essential information that surgical residents and medical students need to have at their fingertips for day-to-day patient care....
... involved with healthcare decisions to keep up ... in their field of interest - a ... the volume of evidence increases. Cochrane Reviews ... single source available for continually updated evidence-based ...
... is a combination of the Medical Spanish pocket ... for PDA. The first part of Medical Spanish ... the Spanish language, i.e. pronunciation, common words and ... and medical terminology. The second part is organized ...
This portable resource provides definitions for medical acronyms and abbreviations....
Medicine Products: